Ascelia Pharma AB (publ) (ACE) - Total Assets
Based on the latest financial reports, Ascelia Pharma AB (publ) (ACE) holds total assets worth Skr136.41 Million SEK (≈ $14.68 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Ascelia Pharma AB (publ) balance sheet quality to measure how much of total assets are equity-financed.
Ascelia Pharma AB (publ) - Total Assets Trend (2016–2024)
This chart illustrates how Ascelia Pharma AB (publ)'s total assets have evolved over time, based on quarterly financial data. Explore ACE long-term investment intensity to see how much of total assets are deployed in long-term investments.
Ascelia Pharma AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2024)
Ascelia Pharma AB (publ)'s total assets of Skr136.41 Million consist of 59.4% current assets and 40.6% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 53.4% |
| Accounts Receivable | Skr5.68 Million | 4.0% |
| Inventory | Skr-6.08 Million | -4.3% |
| Property, Plant & Equipment | Skr124.00K | 0.1% |
| Intangible Assets | Skr57.08 Million | 40.5% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Ascelia Pharma AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ACE market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ascelia Pharma AB (publ)'s current assets represent 59.4% of total assets in 2024, an increase from 29.0% in 2016.
- Cash Position: Cash and equivalents constituted 53.4% of total assets in 2024, up from 2.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 40.0% of total assets, a decrease from 70.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 40.5% of total assets.
Ascelia Pharma AB (publ) Competitors by Total Assets
Key competitors of Ascelia Pharma AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Ascelia Pharma AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.60 | 3.77 | 10.69 |
| Quick Ratio | 3.60 | 3.77 | 10.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr56.45 Million | Skr76.36 Million | Skr177.96 Million |
Ascelia Pharma AB (publ) - Advanced Valuation Insights
This section examines the relationship between Ascelia Pharma AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.56 |
| Latest Market Cap to Assets Ratio | 0.29 |
| Asset Growth Rate (YoY) | 61.8% |
| Total Assets | Skr140.92 Million |
| Market Capitalization | $41.03 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ascelia Pharma AB (publ)'s assets below their book value (0.29x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Ascelia Pharma AB (publ)'s assets grew by 61.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Ascelia Pharma AB (publ) (2016–2024)
The table below shows the annual total assets of Ascelia Pharma AB (publ) from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr140.92 Million ≈ $15.17 Million |
+61.84% |
| 2023-12-31 | Skr87.07 Million ≈ $9.37 Million |
-60.16% |
| 2022-12-31 | Skr218.57 Million ≈ $23.52 Million |
-34.46% |
| 2021-12-31 | Skr333.49 Million ≈ $35.89 Million |
+30.59% |
| 2020-12-31 | Skr255.37 Million ≈ $27.48 Million |
+2.06% |
| 2019-12-31 | Skr250.23 Million ≈ $26.93 Million |
-12.94% |
| 2018-12-31 | Skr287.42 Million ≈ $30.93 Million |
+147.46% |
| 2017-12-31 | Skr116.15 Million ≈ $12.50 Million |
+44.48% |
| 2016-12-31 | Skr80.39 Million ≈ $8.65 Million |
-- |
About Ascelia Pharma AB (publ)
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment o… Read more